Mitchell H. Finer, Ph.D.

Executive Partner, MPM Capital; President of R&D, ElevateBio; CEO, Life Edit Therapeutics

For more than three decades, Mitch Finer has focused on drug development utilizing the novel platforms of cell and gene therapy, cancer immunotherapy and regenerative medicine, and he has held several senior leadership roles in companies developing these therapies.

As executive partner of MPM Capital, Mitch has been instrumental in founding, building and leading a number of MPM portfolio companies. He currently serves as the president of R&D at ElevateBio, a cell and gene therapy technology company, as well as president of BaseCamp, ElevateBio’s centralized R&D and manufacturing company. He is also the founder and former CEO and current executive chairman of Oncorus, founder and former CEO of CODA Biotherapeutics, and currently serves on several MPM portfolio company boards, including CODA, ElevateBio and Oncorus.

Prior to joining MPM, Mitch served as chief scientific officer of bluebird bio. Before that, he was CEO of Intracel Corporation and Genteric, vice president research for Cell Genesys and the Gencell division of Aventis Pharma (now Sanofi) and senior vice president of development at Novacell (now Viacyte). He also successfully co-founded a retinal disease gene therapy company, Avalanche Biotechnologies (now Adverum Biotechnologies).

Mitch has been named inventor on 15 issued U.S. patents in the field of engineered proteins, cells and viruses in the fields of gene therapy of orphan disease, regenerative medicine and immune oncology.

Mitch holds a Ph.D. in biochemistry and molecular biology from Harvard University. He completed a postdoctoral fellowship at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology.

Back to all posts